We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Lumos Diagnostics Holdings Ltd

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test technology to... read more Featured Products: More products

Download Mobile App




10-Minute POC Test Detects and Differentiates Bacterial from Viral Respiratory Infection

By LabMedica International staff writers
Posted on 05 Jul 2023
Print article
Image: FebriDx uses a fingerstick blood sample to differentiate bacterial from viral infections (Photo courtesy of Lumos)
Image: FebriDx uses a fingerstick blood sample to differentiate bacterial from viral infections (Photo courtesy of Lumos)

Acute respiratory infections, which present symptoms such as a sore throat, cough, and runny nose, are the leading cause of doctor appointments and antibiotic prescriptions. However, diagnosing these conditions can be challenging due to the similar symptoms presented by bacterial and viral infections. Despite the fact that the majority of these infections are viral and do not necessitate antibiotics, they are prescribed in almost 58% of cases, when they're only necessary in about 11%. This overprescription of antibiotics significantly contributes to the rising global threat of antimicrobial-resistant (AMR) bacterial strains. Now, a quick fingerstick blood test capable of distinguishing between viral and bacterial acute respiratory infections within 10 minutes can help doctors apply antibiotics where they're truly needed, thereby combating antibiotic resistance.

The inability to easily distinguish between viral and bacterial infections due to similar symptoms, along with lengthy laboratory test results, is the primary reason for antibiotic misuse. This diagnostic uncertainty, combined with doctors' fear of overlooking bacterial infections and patients' expectations of receiving a prescription, often results in unnecessary antibiotic use. The FebriDx rapid, point-of-care test from Lumos Diagnostics (Melbourne, Australia) assists in diagnosing bacterial acute respiratory infections and differentiating them from non-bacterial causes in patients in urgent or emergency care settings. FebriDx is intended for use along with other clinical and laboratory findings to assess patients with acute respiratory infections.

Determining whether a patient has a viral or bacterial infection could greatly decrease unnecessary antibiotic prescriptions, curb the spread of antibiotic-resistant bacteria, and guide medical practitioners on when to start treatment. The use of a rapid screening test like FebriDx during a patient's visit can help ensure appropriate patient management and streamline practice workflow. The results from FebriDx are available within 10 minutes, enabling the clinician to provide a timely and targeted treatment plan during the initial consultation. Lumos has obtained approval from the US Food and Drug Administration (FDA) to market FebriDx in the United States. The test is also registered in the UK, Europe, Canada, UAE, Brazil, Turkey, Pakistan, Singapore, Malaysia, and Australia.

"We are delighted to finally secure clearance to market our FebriDx rapid, point–of–care test in the US as we continue to believe it has an important role to play in antibiotic stewardship," said Doug Ward, CEO of Lumos Diagnostics.

Related Links:
Lumos Diagnostics

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
New
Gold Supplier
Digital Pathology Solution
Dynamyx
New
Near-Patient Testing Platform
FINDER
New
Pipettors
Corning Lambda EliteTouch

Print article
GLOBETECH PUBLISHING LLC

Channels

Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: A CRISPR technology-based diagnostic test detects MPXV in clinical samples with acute precision (Photo courtesy of 123RF)

Powerful Diagnostic Tool Accurately Detects Monkeypox Virus Faster Than Any Method

At present, testing for the monkeypox virus (MPXV) is done mainly in centralized labs, and it can take days to get results due to location and logistical issues. Now, researchers have leveraged cutting-edge... Read more

Hematology

view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more

Immunology

view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more

Microbiology

view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more

Pathology

view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.